Pushpinder Kanda

Pushpinder Kanda

Auto-generated profile, based on publicly available information

Pushpinder Kanda

University of Ottawa, Faculty of Medicine, Department of Ophthalmology, Ottawa, Ontario, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2021 in Eye
Verified
Journal Article
Closed access
PDF file
PKPushpinder Kanda
Pushpinder Kanda
AGArnav Gupta
Arnav Gupta
CGChloe Gottlieb
Chloe Gottlieb
RKRustum Karanjia
Rustum Karanjia
SCStuart G. Coupland
Stuart G. Coupland
MBManpartap Singh Bal
Manpartap Singh Bal

30 March 2023 in IDCases
Verified
Journal Article
Open access
PKPushpinder Kanda
Pushpinder Kanda
SISarantos Ioannidis
Sarantos Ioannidis
WSWei Sim
Wei Sim
BWBonnie Weston
Bonnie Weston
MKMona Koaik
Mona Koaik
Primary meningococcal conjunctivitis from Neisseria meningitidis is a rare cause for acute, purulent conjunctivitis most commonly presenting in children. Here we present a case of primary meningococcal conjunctivitis in an adult patient with mild signs/symptoms mimicking non-gonococcal bacterial conjunctivitis. The patient was immediately treated with topical and systemic antibiotics. Here we highlight that an early diagnosis of a mild case can be missed thus, clinicians need to keep a high index of suspension as prompt recognition is important to initiate appropriate systemic antimicrobial therapy to prevent systemic disease.

10 April 2024 in Eye
Verified
Journal Article
Closed access
PDF file
PKPushpinder Kanda
Pushpinder Kanda
AGArnav Gupta
Arnav Gupta
JDJobanpreet Dhillon
Jobanpreet Dhillon
DKDeeksha Kundapur
Deeksha Kundapur
CGChloe C. Gottlieb
Chloe C. Gottlieb

11 November 2021 in Documenta Ophthalmologica
Verified
Journal Article
Open access
PDF file
ATAdrian Tsang
Adrian Tsang
PKPushpinder Kanda
Pushpinder Kanda
CGChloe Gottlieb
Chloe Gottlieb
GVGianni Virgili
Gianni Virgili
LKLynca Kantungane
Lynca Kantungane
SCStuart Coupland
Stuart Coupland
Purpose: Multifocal electroretinogram (mfERG) shows great utility as a screening tool to detect early hydroxychloroquine (HCQ) retinopathy, but its widespread use is limited by the lack of accessibility and long test duration. In this study, we evaluated a novel concentric 5-ring mfERG stimulus to provide a simplified and rapid protocol for screening HCQ toxicity. Methods: Patients referred for HCQ retinopathy screening were consented to this observational cross-sectional study. Patients with amblyopia, high refractive error (more than 8 diopters), other retinal diseases precluding appropriate evaluation or history of retinal surgery were excluded. The data were collected from patients undergoing HCQ screening at a single center from July 2019 to March 2020. Patients were tested with the new concentric 5-ring mfERG stimulus, standard 61-hexagon mfERG stimulus, spectral domain optical coherence tomography and automated 10-2 visual fields. For the main outcome, the 5-ring mfERG was compared to 61-hexagon stimulus to determine the time-to-test completion and assess the association between ring (R1–R5) amplitude and ring ratio compared against cumulative dose, dose by real body weight and duration of therapy using Pearson correlation. Results: In total, 52 patients (104 eyes; 5 males and 47 females) were recruited with a mean age of 59 years (range 23–85 years). The 5-ring protocol was markedly quicker to perform (1.3 ± 0.2 min; mean (SD)) compared to the 61-hexagon protocol (5.2 ± 0.6 min), p < 0.0001; n = 10 patients. The new R2/R5 ring ratio showed a moderate correlation with daily dose (r = − 0.640), cumulative dose (r = − 0.581) and duration of therapy (r = − 0.417). Similar correlations were observed with the new R2/R4 ring ratio which were not significantly different from the new R2/R5 correlation coefficients. The new R2/R5 ring ratio demonstrated a stronger correlation with daily (p = 0.002) and cumulative dose (p = 0.0001) compared to the 61-hexagon stimulus. Conclusions: In this exploratory study, our novel 5-ring mfERG protocol significantly shortened data acquisition time while providing comparable results to the standard 61-hexagon stimulus for detecting HCQ-induced electrophysiological changes that are correlated with HCQ dosages and treatment duration. Our protocol has the potential to be more clinically practical by simplifying routine screening.

8 September 2020
Verified
Book Chapter
Closed access
PDF file
VHVictor H. Hu
Victor H. Hu
PKPushpinder Kanda
Pushpinder Kanda
KMKamal Malhotra
Kamal Malhotra
EAEmilio Alarcon
Emilio Alarcon
MGMiguel González-Andrades
Miguel González-Andrades
MGMay Griffith
May Griffith

24 April 2024 in Frontiers in Ophthalmology
Verified
Journal Article
Open access
PDF file
PKPushpinder Kanda
Pushpinder Kanda
IGIsaura Guerrero-Córdova
Isaura Guerrero-Córdova
JDJobanpreet Dhillon
Jobanpreet Dhillon
ATAdrian Tsang
Adrian Tsang
Introduction: Zoledronate is a commonly prescribed medication to maintain bone health; however, a rare side effect includes ocular inflammation. We report a case of simultaneous anterior uveitis and orbital inflammation associated with zoledronate infusion in a patient with metastatic breast cancer. We also performed a literature search to provide an up-to-date summary of cases with zoledronate-associated ocular inflammation.Methods: This is a case report with literature review. Literature search (timeline 2010 to 2023) was performed using PubMed with the search team: (zoledronate) AND (uveitis OR scleritis OR orbital inflammation OR ocular inflammation).Results: A 48-year-old female presented with left eye pain, swelling, and decreased vision 2 days after receiving zoledronic acid infusion. An ophthalmic exam showed non-granulomatous anterior uveitis. CT orbits and ocular ultrasound showed signs of posterior scleritis and orbital inflammation. Ocular inflammation caused by an infection or metastatic cancer was ruled out. The patient was treated with both topical and systemic corticosteroids. Complete resolution of the inflammation occurred after 2.5 weeks.Conclusion: Orbital inflammation and uveitis are an uncommon side effect of zoledronate but needs to be promptly recognized and treated to prevent sight-threatening complications.